Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Othman Al-Sawaf; Sandra Robrecht; Can Zhang; Stefano Olivieri; Yi Meng Chang; Anna Maria Fink; Eugen Tausch; Christof Schneider; Matthias Ritgen; Karl-Anton Kreuzer

doi:10.1182/blood.2024024631

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Identifier:nobleid.org/w1/20260526/D030BAC7

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D030BAC7.svg?ark=w1%2F20260526%2FD030BAC7)](https://nobleid.org/work/w1/20260526/D030BAC7)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Identifier:nobleid.org/w1/20260526/D030BAC7

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D030BAC7.svg?ark=w1%2F20260526%2FD030BAC7)](https://nobleid.org/work/w1/20260526/D030BAC7)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work